Table 1 Demographics of the four study groups (N = 93).

From: Characterization of basal ganglia volume changes in the context of HIV and polysubstance use

 

HIV-/POLY− (n = 34)

HIV− /POLY + (n = 27)

HIV + /POLY− (n = 17)

HIV + /POLY + (n = 15)

P-value

Age years (SD)

50.92 (12.6)

46.09(11.8)

57.28 (9.0)

56.53 (4.3)

0.129A-B, 0.045A-C, 0.100A-D, 0.001B-C, 0.002B-D, 0.765C-D

Sex M:F

19:15

15:12

16:1

9:6

0.980A-B, 0.006A-C, 0.788A-D, 0.006B-C, 0.780B-D, 0.020C-D

Education years (SD)

14.37 (2.1)

12.14 (1.5)

15.06 (2.0)

13.07 (2.2)

 < 0.001A-B, 0.258A-C, 0.062A-D, < 0.001B-C, 0.159B-D, 0.012C-D

Handedness R:L:A

30:1:3

24:1:2

14:3:0

11:2:2

N.S

RAB (SD)

8.00 (4.7)

26.84 (13.7)

9.14 (3.1)

23.14 (11.7)

0.001A-B, 0.951A-C, < 0.001A-D, < 0.001B-C, 0.842B-D, < 0.001C-D

BIS-11 (SD)

61.00 (16.5)

89.64 (11.3)

66.47 (13.3)

80.60 (19.6)

0.002A-B, 0.573A-C, 0.002A-D, 0.002B-C, 0.837B-D, 0.011C-D

  1. When a variable contained data from all 4 groups, an ANOVA (or Pearson Chi-Square for categorical variables) was performed first in order to determine significant group differences. Statistics from post-hoc comparison are reported in the table as follows: A = HIV-/POLY-, B = HIV-/POLY + , C = HIV + /POLY-, D = HIV + /POLY + . Group comparisons are indicated by the two letters as marked (e.g., A-B indicates Group A vs. Group B). N.S. = not significant, per original omnibus test and no post-hoc comparisons were conducted; SD = standard deviation, M:F = male: female, R:L:A = right: left: ambidextrous. Boldface indicates significance, p < .05.